FDA Grants Accelerated Approval to Iberdomide in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone as Treatment for Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-accelerated-approval-iberdomide-dara-dex-rrmm)